What changed, and when

Eli Lilly and Centessa announced a definitive agreement on 31 Mar 2026 for Lilly to acquire Centessa for $38.00 per share in cash plus one non-transferable CVR worth up to $9.00 per share, implying up to $47.00 per share and total potential equity value of about $7.8 billion. The transaction is structured as a scheme of arrangement under English law and is expected to close in Q3 2026, subject to shareholder, court, and regulatory approvals. (Lilly announcement, Centessa filing, Reuters)

60-second thesis frame

Confidence rises because Lilly is buying a focused orexin receptor 2 agonist platform, not a single-asset story: cleminorexton has shown mid-stage signal across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, while ORX142 and ORX489 give follow-on optionality. (Centessa pipeline, Centessa Q3 2025 update, Fierce Biotech) Confidence stays capped because the value creation still depends on registrational execution, FDA approvals tied to the CVR, and commercial proof in rare sleep-wake disorders where trial design, label scope, and access policy can all compress peak value. (ClinicalTrials.gov NCT07096674, CTIS ORX750-0201, Reuters)

The seven diligence questions

Clinical

• How durable is cleminorexton’s efficacy signal beyond the early crossover cohorts, especially in NT2 and IH where ORX biology is mechanistically promising but commercial and regulatory precedent is thinner? (Centessa Q3 2025 update, ClinicalTrials.gov NCT07096674)
• Does the observed tolerability profile, including pollakiuria, insomnia, dizziness, and headache, remain manageable at higher doses and in longer exposure, particularly if Lilly pushes for broader wakefulness indications? (Centessa Q3 2025 update)

Payer or Access

• Will payers view NT2 and IH as premium orphan-neuro categories with manageable budget impact, or as step-through extensions of existing wake-promoting agents that require aggressive prior auth?
• How much label language will Lilly need on functional outcomes, cataplexy, and comparative differentiation to win preferred access versus incumbent stimulants and newer orexin approaches? (Centessa Q3 2025 update, Reuters)

Ops or Adoption

• Can Lilly accelerate the registrational path without losing the clinical nuance needed across three distinct patient groups and potentially multiple dosing regimens? (Centessa Q3 2025 update, Centessa filing)

Competitive

• Does this deal give Lilly a genuine lead in OX2R agonists, or does it simply validate a class that could see rival interest around Alkermes, Takeda, or even a counterbid for Centessa before close? (Reuters, STAT, paywalled, Fierce Biotech, free alternative)

Team or Cap table

• How important are Mario Accardi and the Centessa orexin team to preserving program velocity post-close, and how much of the de-risking already comes from investor support agreements covering about 24.1% of shares? (Lilly announcement, Centessa filing, Fierce Biotech)

Red flags

• The CVR tells you Lilly is sharing regulatory risk with sellers, not underwriting full value upfront, which is a healthy signal but also a reminder that approval timing and indication sequence are still uncertain. (Lilly announcement, Reuters)
• Early efficacy data are promising, but the publicly cited Phase 2a evidence still comes from relatively small cohorts and short crossover exposure, which can overstate real-world durability. (Centessa Q3 2025 update, ClinicalTrials.gov NCT07096674)
• The deal premium looks less aggressive than many breakout-neuro acquisitions, which Reuters notes has prompted analyst discussion of possible rival bids; even if no bid emerges, that tells you the market still debates intrinsic value. (Reuters, STAT, paywalled, Fierce Biotech, free alternative)

Next catalyst

Acquisition process milestones are the nearest hard catalyst, proxy materials, shareholder vote, court sanction, and regulatory clearances ahead of the targeted Q3 2026 close. Clinical follow-through on the cleminorexton registrational path is the next value catalyst after that. (Centessa filing, Lilly announcement)

FAQ

What exactly changed by Lilly’s acquisition of Centessa news on 31 Mar 2026, and why does it matter for the sleep-wake market?

Lilly agreed to acquire Centessa for $38.00 per share in cash plus a CVR worth up to $9.00 per share, for total potential value of about $7.8 billion. (Lilly announcement, Reuters) The deal matters because it gives Lilly a direct entry into orexin-based sleep medicine through cleminorexton and a broader OX2R platform, expanding beyond its metabolic franchise into neuroscience.( Centessa pipeline, Fierce Biotech)

What is the regulatory path after the Eli Lilly Centessa acquisition news on 31 Mar 2026, and what are the next formal steps?

The transaction will be implemented by a scheme of arrangement under the laws of England and Wales, with closing expected in Q3 2026 subject to Centessa shareholder approval, High Court sanction, and regulatory approvals. (Lilly announcement, Centessa filing) On the asset side, the long-term extension trial for ORX750 is already listed on ClinicalTrials.gov, which supports the view that the program is preparing for longer-duration development while Lilly takes control. (ClinicalTrials.gov NCT07096674, CTIS ORX750-0201)

Which endpoints in Centessa’s ORX750 program drove the result cited in Eli Lilly and Centessa’s announcement, and how meaningful was the effect size?

Centessa’s November 2025 update highlighted statistically significant and clinically meaningful improvements versus placebo on Maintenance of Wakefulness Test, Epworth Sleepiness Scale, and, in NT1, Weekly Cataplexy Rate. (Centessa Q3 2025 update) In the disclosed cohorts, the 1.5 mg NT1 group showed more than a 20-minute change from baseline in mean sleep latency on MWT versus placebo and an 87% relative reduction in weekly cataplexy rate, while NT2 and IH cohorts also showed significant wakefulness gains. (Centessa Q3 2025 update)

What safety issues matter after the news regarding the Centessa acquisition by Eli Lilly and do they change how investors should frame risk?

The disclosed ORX750 dataset described adverse events as transient and mild to moderate, with common treatment-emergent events including pollakiuria, insomnia, dizziness, and headache, and one discontinuation due to urinary urgency in NT2. (Centessa Q3 2025 update) That does not break the thesis, but it does focus diligence on dose optimization, persistence, nighttime tolerability, and whether broadening into larger studies changes the profile.(Centessa Q3 2025 update)

How will major US payers treat access after this deal, and are codes available?

Payers typically place new narcolepsy drugs on high-cost specialty tiers requiring prior authorization (DelveInsight). While specific J-codes or CPT codes for cleminorexton will not be available until after FDA approval, Lilly’s commercial scale is expected to facilitate broad formulary negotiations against incumbents (PharmExec).

Publisher / Disclosure

Publisher: LucidQuest Ventures Ltd. Produced: 03 Apr 2026, 05:07 London. Purpose: general and impersonal information. Not investment research or advice, no offer or solicitation, no suitability assessment. UK: directed at investment professionals under Article 19(5) and certain high-net-worth entities under Article 49(2)(a)–(d) of the Financial Promotion Order 2005. Others should not act on this. Sources and accuracy: public sources believed reliable, provided “as is,” may change without notice. No duty to update. Past performance is not reliable. Forward-looking statements carry risks. Methodology: questions-first framework using public sources. No conflicts. Authors do not hold positions unless stated. © 2026 LucidQuest Ventures Ltd.

Entities / Keywords

Eli Lilly; Centessa Pharmaceuticals; cleminorexton; ORX750; ORX142; ORX489; OX2R agonist; orexin receptor 2; narcolepsy type 1; narcolepsy type 2; idiopathic hypersomnia; excessive daytime sleepiness; CRYSTAL-1; NCT07096674; ORX750-0201; CVR; scheme of arrangement; England and Wales High Court; neuroscience; sleep-wake disorders; rare disease; market access; payer access; FDA; ClinicalTrials.gov; CTIS; Medicxi Ventures; Index Ventures; General Atlantic; Carole Ho; Mario Accardi; Lilly Neuroscience; wakefulness; cataplexy; ESS; MWT; Q3 2026 close

Find more Lucid Diligence Briefs here.